| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3427 | Mmv001239 | Novel inhibitor of lanosterol-14-alpha-demethylase (TcCyp51) |
|
| DCC3428 | Mmv006764 | The first small-molecule anti-plasmodial agent, disrupting rosetting, simultaneously restoring microcirculation and reduce parasite load |
|
| DCC3429 | Mmv007564 | Novel antimalarial agent against asexual stages of P. falciparum |
|
| DCC3430 | Mmv007839 | Novel potent Plasmodium lactate transporter PfFNT |
|
| DCC3431 | Mmv008138 | Novel MEP pathway-targeting antimalarial agent |
|
| DCC3432 | Mmv009108 | Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones |
|
| DCC3433 | Mmv019662 | Novel Inhibitor of Plasmodium falciparum |
|
| DCC3434 | Mmv022029 | Novel antischistosomal agent against chronic S. mansoni infection |
|
| DCC3435 | Mmv022478 | Novel antischistosomal agent against chronic S. mansoni infection |
|
| DCC3436 | Mmv028038 | Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones |
|
| DCC3437 | Mmv085203 | Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites |
|
| DCC3438 | Mmv396719 | Novel antimalarial agent against Plasmodium falciparum |
|
| DCC3439 | Mmv665916 | Novel antimalarial agent, targeting P. falciparum farnesyltransferase PfFT, showing remarkable growth inhibition with EC50 value of 0.4 µM and presenting good selectivity index (SI > 250) |
|
| DCC3440 | Mmv666693 | Selective allosteric inhibitor of Plasmodium Kinesin-5 |
|
| DCC3441 | Mmv675939 | Novel potent inhibitor of P. falciparum asexual blood stages, inhibiting heme detoxification |
|
| DCC3442 | Mmv676477 | Novel potent broad antiparasitic agent against intracellular Leishmania amastigotes, Trypanosoma brucei, and Plasmodium falciparum |
|
| DCC3443 | Mmv693183 | First-in-class acetyl-CoA synthetase (AcAS) inhibitor, showong single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocking P. falciparum transmission to Anopheles mosquitoes |
|
| DCC3444 | Mnd Oxalate | Novel anticancer agent, inducing apoptosis, inhibiting migration and invasion |
|
| DCC3445 | Mnk1/2-in-9 | Novel highly potent and selective MNK1/2 kinases inhibitor |
|
| DCC3446 | Mnk2-in-8e | Potent and selective Mnk2 inhibitor |
|
| DCC3447 | Mntmpyp Pentachloride | Cell-permeable superoxide dismutase (SOD) mimetic |
|
| DCC3448 | Molibresib Besylate | Novel inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity |
|
| DCC3449 | Momelotinib Dihydrochloride Featured | Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis. |
|
| DCC3450 | Momordicoside L | Natural antioxidant and antidiabetic agent |
|
| DCC3451 | Mon-dnj | Novel iminosugar, downregulatiing the interferon γ receptor by dengue virus |
|
| DCC3452 | Moracin T | Natural potent antioxidant agent |
|
| DCC3453 | Morellic Acid | Natural analogue of (-)-gambogic acid acting as a potent inhibitor of global predominant MRSA USA300 |
|
| DCC3454 | Mosapramine Dihydrochloride | Potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors, and with moderate affinity for the 5-HT2 receptors |
|
| DCC3455 | Naucledine | Natural antibacterial, antileishmanial, and antifungal agent |
|
| DCC3456 | Mp-10 Succinate | Potent and Specific PDE10A inhibitor |
|
